Lazard Asset Management
TCRX icon

Lazard Asset Management’s TScan Therapeutics TCRX Stock Holding History

Lazard Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-70
Closed – – 2573
2024
Q4 		$0 Hold
70
– – ﹤0.01% 2532
2024
Q3 		$0 Sell
70
-106
-60% -$640 ﹤0.01% 2452
2024
Q2 		$0 Sell
176
-2,375
-93% -$18.7K ﹤0.01% 2425
2024
Q1 		$19K Sell
2,551
-1,432
-36% -$9.01K ﹤0.01% 1846
2023
Q4 		$22K Buy
+3,983
New +$18.2K ﹤0.01% 2049

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Lazard Asset Management's TCRX Position: Q1 2025 in Review

Lazard Asset Management sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 70 shares.

Lazard Asset Management first reported a position in TCRX in Q4 2023 and held it in 5 quarters. The position peaked at $22K in Q4 2023. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • Lazard Asset Management reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 70 TScan Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in TScan Therapeutics in Q4 2023 and held it in 5 quarters.
  • Lazard Asset Management's TScan Therapeutics position peaked at $22K in Q4 2023.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.